Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: A prospective, real-life, observational study

World Journal of Gastroenterology

Volumn 14, Issue 40, 2008, Pages 6195-6203

  Cacoub, Patrice ^a,i   Ouzan, Denis ^b   Melin, Pascal ^c   Lang, Jean Philippe ^d   Rotily, Michel ^e   Fontanges, Thierry ^f   Varastet, Marina ^e   Chousterman, Michel ^g   Marcellin, Patrick ^h,j  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT ARNAULT TZANCK   (France)

^c Hospital of Saint Dizier   (France)

^d Hospital of Erstein   (France)

^e ClinSearch   (France)

^f General Hospital of Bourgoin   (France)

^g CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^h BEAUJON HOSPITAL   (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

more..

Author keywords

Adherence; Peg interferon; Real life; Ribavirin; Therapeutic education; Viral hepatitis

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA2B INTERFERON; ANTIVIRUS AGENT; PEGINTERFERON ALFA-2B;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEALTH EDUCATION; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RECURRENCE RISK; RECURRENT DISEASE; RNA ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; ATTITUDE TO HEALTH; BLOOD; DRUG COMBINATION; DRUG EFFECT; EPIDEMIOLOGY; FRANCE; GENETICS; HEPATITIS C VIRUS; MIDDLE AGED; PROSPECTIVE STUDY; RISK; RISK ASSESSMENT; TIME; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; GENOTYPE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; PATIENT EDUCATION AS TOPIC; PROSPECTIVE STUDIES; RIBAVIRIN; RISK ASSESSMENT; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 63449113491     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.6195     Document Type: Article

References (31)

1. Sabate E. Adherence to long-term therapies. Evidence for action. Geneva: World Health Organization; 2003. Available from URL: http://whqlibdoc.who.int/publications/2003/9241545992.pdf
2. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497
3. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333: 15
4. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003; 6: 566-573
5. Waeber B, Leonetti G, Kolloch R, McInnes GT. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens 1999; 17: 1041-1045
6. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310
7. Dunbar-Jacob J, Mortimer-Stephens MK. Treatment adherence in chronic disease. J Clin Epidemiol 2001; 54 Suppl 1: S57-S60
8. Camma C, Licata A, Cabibbo G, Latteri F, Craxi A. Treatment of hepatitis C: critical appraisal of the evidence. Expert Opin Pharmacother 2005; 6: 399-408
9. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-1359
10. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, Bernsmeier C, Haussinger D, Herrmann E, Zeuzem S. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-527
11. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Sarrazin C, Harvey J, Brass C, Albrecht J. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-999
12. Moucari R, Ripault MP, Oules V, Martinot-Peignoux M, Asselah T, Boyer N, El Ray A, Cazals-Hatem D, Vidaud D, Valla D, Bourliere M, Marcellin P. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J Hepatol 2007; 46: 596-604
13. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1069
14. Hughes CA, Shafran SD. Chronic hepatitis C virus management: 2000-2005 update. Ann Pharmacother 2006; 40: 74-82
15. Consensus conference. Treatment of hepatitis C. Gastroenterol Clin Biol 2002; 26 Spec No 2: B303-B320
16. Plan National Hépatites Virales C et B (2002-2005). 2002. Available from URL: http://www.sante.gouv.fr/htm/actu/hepatites/ sommaire.htm
17. Balfour L, Cooper C, Tasca GA, Kane M, Kowal J, Garber G. Evaluation of health care needs and patient satisfaction among hepatitis C patients treated at a hospital-based, viral hepatitis clinic. Can J Public Health 2004; 95: 272-277
18. Zickmund S, Hillis SL, Barnett MJ, Ippolito L, LaBrecque DR. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology 2004; 39: 999-1007
19. Zeuzem S, Heathcote EJ, Shiffman ML, Wright TL, Bain VG, Sherman M, Feinman SV, Fried MW, Rasenack J, Sarrazin C, Jensen DM, Lin A, Hoffman JH, Sedarati F. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol 2003; 39: 106-111
20. Moatti JP, Spire B, Duran S. [A review of socio-behavioural studies on adherence to antiretroviral treatments: beyond biomedical models?] Rev Epidemiol Sante Publique 2000; 48: 182-197
21. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med 2002; 19: 279-284
22. Rudd P. Compliance with antihypertensive therapy: raising the bar of expectations. Am J Manag Care 1998; 4: 957-966
23. Mulhall BP, Younossi Z. Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol 2005; 39: S23-S27
24. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
25. Patton K, Meyers J, Lewis BE. Enhancement of compliance among patients with hypertension. Am J Manag Care 1997; 3: 1693-1698
26. Ran MS, Xiang MZ, Chan CL, Leff J, Simpson P, Huang MS, Shan YH, Li SG. Effectiveness of psychoeducational intervention for rural Chinese families experiencing schizophrenia-a randomised controlled trial. Soc Psychiatry Psychiatr Epidemiol 2003; 38: 69-75
27. Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2002; CD000011
28. Simoni JM, Frick PA, Pantalone DW, Turner BJ. Antiretroviral adherence interventions: a review of current literature and ongoing studies. Top HIV Med 2003; 11: 185-198
29. Burnier M. Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension. Blood Press Monit 2000; 5 Suppl 1: S31-S34
30. Misdrahi D, Llorca PM, Lancon C, Bayle FJ. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications] Encephale 2002; 28: 266-272
31. Ross FM. Patient compliance-whose responsibility? Soc Sci Med 1991; 32: 89-94